Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.

@article{Takanashi2013EfficacyAS,
  title={Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.},
  author={Masashi Takanashi and Yasushi Shimo and Taku Hatano and Genko Oyama and Nobutaka Hattori},
  journal={Drug research},
  year={2013},
  volume={63 12},
  pages={639-43}
}
This study aimed to evaluate the efficacy and safety of an extended-release tablet formulation of pramipexole (PPX-ER) given once daily when switched from an immediate-release tablet formulation (PPX-IR) given 3 times daily. This open-label study included 29 patients with idiopathic Parkinson's disease (PD) who were followed for 8 weeks. Primary endpoints were Unified Parkinson's Disease Rating Scale (UPDRS) part III score, a physician evaluation of motor symptoms; nocturnal and early morning… CONTINUE READING

Similar Papers

Loading similar papers…